Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1039 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... January 26, 2022 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... December 4, 2020 Load more HOT NEWS FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma Expanding the horizons of the life science economy The Mediterranean Diet EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan
